MELISSA HOGAN: Open Payments
NPI 1023475688 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,821 in 100 payments from 10 companies in 2025. Trend: 2023 $923 · 2024 $1,205 · 2025 $1,821
Food & beverage: $1,817Education: $4
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 22 | $368 |
| Vanda Pharmaceuticals Inc. | 11 | $310 |
| Neurocrine BioSciences, Inc. | 14 | $286 |
| Indivior Inc. | 14 | $233 |
| Alkermes, Inc. | 14 | $208 |
| E.R. Squibb & Sons, L.L.C. | 11 | $159 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $72 |
| Lundbeck LLC | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
Products named: FANAPT, INGREZZA, INVEGA SUSTENNA, SUBLOCADE, COBENFY, ARISTADA, SPRAVATO, REXULTI.
Industry payments across OK — which companies pay providers there.
